tiprankstipranks
Trending News
More News >
CERo Therapeutics Holdings (CERO)
NASDAQ:CERO
US Market

CERo Therapeutics Holdings (CERO) Ratios

Compare
379 Followers

CERo Therapeutics Holdings Ratios

CERO's free cash flow for Q3 2024 was $0.00. For the 2024 fiscal year, CERO's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.
Ratios
TTM
Dec 23Dec 22Dec 21
Liquidity Ratios
Current Ratio
1.65 1.38 13.88
Quick Ratio
1.65 1.38 13.88
Cash Ratio
0.02 1.37 11.20
Solvency Ratio
<0.01 0.01 0.05
Operating Cash Flow Ratio
>-0.01 -0.04 -7.11
Short-Term Operating Cash Flow Coverage
>-0.01 -1.68 0.00
Net Current Asset Value
$ -14.20M$ 2.47M$ -7.89M
Leverage Ratios
Debt-to-Assets Ratio
0.18 0.02 0.02
Debt-to-Equity Ratio
-0.11 0.26 0.02
Debt-to-Capital Ratio
-0.12 0.21 0.02
Long-Term Debt-to-Capital Ratio
0.00 0.00 0.02
Financial Leverage Ratio
-0.60 17.16 1.05
Debt Service Coverage Ratio
-1.63 -1.03 0.00
Interest Coverage Ratio
0.00 0.00 0.00
Debt to Market Cap
<0.01 <0.01 <0.01
Interest Debt Per Share
0.24 0.10 0.16
Net Debt to EBITDA
-0.60 605.04 -7.54
Profitability Margins
Gross Profit Margin
0.00%0.00%0.00%
EBIT Margin
0.00%0.00%0.00%
EBITDA Margin
0.00%0.00%0.00%
Operating Profit Margin
0.00%0.00%0.00%
Pretax Profit Margin
0.00%0.00%0.00%
Net Profit Margin
0.00%0.00%0.00%
Continuous Operations Profit Margin
0.00%0.00%0.00%
Net Income Per EBT
0.10%973.70%94.93%
EBT Per EBIT
83.24%2.36%100.12%
Return on Assets (ROA)
-0.03%-1.58%-0.18%
Return on Equity (ROE)
0.02%-27.05%-0.18%
Return on Capital Employed (ROCE)
-86.59%-25.01%-0.18%
Return on Invested Capital (ROIC)
-61.65%-171.02%-0.18%
Return on Tangible Assets
-0.03%-1.58%-0.17%
Earnings Yield
>-0.01%>-0.01%>-0.01%
Efficiency Ratios
Receivables Turnover
0.00 0.00 0.00
Payables Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00
Working Capital Turnover Ratio
0.00 0.00 0.00
Cash Conversion Cycle
0.00 0.00 0.00
Days of Sales Outstanding
0.00 0.00 0.00
Days of Inventory Outstanding
0.00 0.00 0.00
Days of Payables Outstanding
0.00 0.00 0.00
Operating Cycle
0.00 0.00 0.00
Cash Flow Ratios
Operating Cash Flow Per Share
>-0.01 -0.16 -0.03
Free Cash Flow Per Share
>-0.01 -0.26 -0.06
CapEx Per Share
<0.01 0.10 0.03
Free Cash Flow to Operating Cash Flow
1.00 1.64 1.88
Dividend Paid and CapEx Coverage Ratio
-380.90 -1.57 -1.14
Capital Expenditure Coverage Ratio
-380.90 -1.57 -1.14
Operating Cash Flow Coverage Ratio
>-0.01 -1.68 -0.19
Operating Cash Flow to Sales Ratio
0.00 0.00 0.00
Free Cash Flow Yield
>-0.01%-0.03%>-0.01%
Valuation Ratios
Price-to-Earnings (P/E) Ratio
-2.83M -10.41K -72.17K
Price-to-Sales (P/S) Ratio
0.00 0.00 0.00
Price-to-Book (P/B) Ratio
-505.72 2.82K 133.32
Price-to-Free Cash Flow (P/FCF) Ratio
-4.73M -3.89K -17.39K
Price-to-Operating Cash Flow Ratio
-4.71M -6.37K -32.67K
Price-to-Earnings Growth (PEG) Ratio
-9.58K -16.80 0.00
Price-to-Fair Value
-505.72 2.82K 133.32
Enterprise Value Multiple
-2.94K -100.77K -68.60K
EV to EBITDA
-2.94K -100.77K -68.60K
EV to Sales
0.00 0.00 0.00
EV to Free Cash Flow
-4.73M -3.87K -17.39K
EV to Operating Cash Flow
-4.71M -6.33K -32.67K
Tangible Book Value Per Share
-2.18 0.36 7.43
Shareholders’ Equity Per Share
-2.18 0.36 7.43
Tax and Other Ratios
Effective Tax Rate
-0.04 -8.74 0.05
Revenue Per Share
0.00 0.00 0.00
Net Income Per Share
>-0.01 -0.10 -0.01
Tax Burden
<0.01 9.74 0.95
Interest Burden
1.00 0.02 1.00
Research & Development to Revenue
0.00 0.00 0.00
SG&A to Revenue
0.00 0.00 0.00
Stock-Based Compensation to Revenue
0.00 0.00 0.00
Income Quality
0.60 1.64 2.21
Currency in USD
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis